NuMe Health is a New Orleans-based biotech startup developing products that modify the bacteria that live in the gastrointestinal tract. It is led by CEO Dean P. Stull, PhD. The company's lead cobiotic product, NM504, is being developed for the prediabetic population to support maintenance of healthy blood glucose levels and metabolic fitness. NuMe is initiating a clinical trial of NM504 and plans to use recent funding to advance the program toward commercialization. The company intends to develop the initial format for its first consumer product, complete a pilot clinical trial, and prepare for an initial direct-to-consumer launch. Financially, NuMe raised $1.5M in a Series A financing to support these efforts.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

May 2012